Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04819074Unknown

Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms

Role: collaborator

NCT02285023Completed

The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire

Role: collaborator

NCT01965717Completed

Multicentre Trial Of Serum Levels Of MMP-9 As A Biomarker Of Endoleak

Role: collaborator

NCT00445822Unknown

Registration of Children With CML and Treatment With Imatinib

Role: collaborator

All 4 trials loaded